产品
编 号：F452122
分子式：C12H13F3N2O2
分子量：274.24
分子式：C12H13F3N2O2
分子量：274.24
产品类型
规格
价格
是否有货
结构图
CAS No: 76263-13-3
产品详情
生物活性：
Fluzinamide is an effective antiepileptic.
体内研究：
Fluzinamide, an antiepileptic agent effective against partial seizures, is metabolized extensively in mice, rats and dogs.The anticonvulsant properties of Fluzinamide (AHR-8559) are evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuates afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that does not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation is seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) is also evaluated in kindled rats using threshold (20 μA increments) seizures. Low doses of Fluzinamide significantly elevate seizure threshold and reduce both elicited after discharge durations and seizure severity. When administered daily during kindling acquisition, Fluzinamide (20 and 40 mg/kg i.p.) significantly increases the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period are reduced.
Fluzinamide is an effective antiepileptic.
体内研究：
Fluzinamide, an antiepileptic agent effective against partial seizures, is metabolized extensively in mice, rats and dogs.The anticonvulsant properties of Fluzinamide (AHR-8559) are evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuates afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that does not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation is seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) is also evaluated in kindled rats using threshold (20 μA increments) seizures. Low doses of Fluzinamide significantly elevate seizure threshold and reduce both elicited after discharge durations and seizure severity. When administered daily during kindling acquisition, Fluzinamide (20 and 40 mg/kg i.p.) significantly increases the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period are reduced.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备